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Asthma guidelines: Why 
aminophylline?
To the Editor: While it is always encouarging to see new clinical 
guidelines to help direct therapy for important clinical conditions, 
the ‘Guidelines for the management of acute asthma in adults’[1] are 
disappointing in two regards. 
Firstly, a majority of acute asthma attacks in adults are managed 
in the emergency centre and/or emergency medical services (EMS) 
setting, and yet no emergency medicine inputs – including those of 
the Emergency Medicine Society of South Africa – were sought or 
included in the guidelines. 
Secondly, while the majority of recommendations are well-
formulated and evidence-based, it is surprising to see the use of 
intravenous aminophylline still promoted: it was removed from 
international guidelines many years ago and the lack of benefit has 
been well proven. Unlike the majority of the recommendations 
in these guidelines, the use of this drug is not accompanied by 
a supporting evidence level. Multiple studies have shown that it 
adds no value over the use of beta-agonists in acute management, 
including the fact that it provides no further bronchodilation above 
that achieved with beta-agonists.[2-4] In addition, it increases the 
incidence of adverse effects when combined with bronchodilators.[3,4] 
To quote from the latest Cochrane review on the matter:[4] ‘The 
use of intravenous aminophylline did not result in significant 
additional bronchodilation compared to standard care with inhaled 
beta2-agonists … or in a significant reduction in the risk of hospital 
admission. For every 100 people treated with aminophylline an 
additional 20 people had vomiting and 15 people arrhythmias or 
palpitations. No subgroups in which aminophylline might be more 
effective were identified.’ 
The continuation of maintenance oral theophylline appears 
reasonable, but the use of intravenous aminophylline has no 
therapeutic benefit, is associated with increased adverse events, and 
should be removed from the guideline. The international and local 
emergency medicine communities did so long ago.
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